We’re only one day away from State of the Biotech Union, Xconomy’s annual Bay Area life sciences forum, which will take place tomorrow afternoon (December 6) at the Amgen Campus in South San Francisco. For you late decision-makers, you’re almost out of time to save on this unique event. Our Procrastinator’s Special rate ends today so act now (and save $100).
We will be holding a series of post-election discussions to assess where biotech and healthcare are heading after the stunning election of Donald Trump.
One more session to highlight:
—After their separate talks, Vijay Pande from Andreessen Horowitz will be joined by Sage Bionetworks’ John Wilbanks to answer questions from the audience.
Confirmed speakers include:
John Wilbanks, Chief Commons Officer, Sage Bionetworks
Vijay Pande, General Partner, Andreessen Horowitz
Peter Kuhn, Dean’s Professor of Biological Sciences; Professor of Medicine and Engineering, USC
Jacob Corn, Scientific Director, Innovative Genomics Initiative, UC Berkeley
Melanie Ott, Senior Investigator, Gladstone Institute of Virology and Immunology, UCSF
Marcy Darnovsky, Executive Director, Center for Genomics and Society
Camille Samuels, Partner, Venrock
Duncan MacCannell, CSO, OAMD, Centers for Disease Control and Prevention
Matthew Porteus, Associate Professor of Pediatrics (Stem Cell Transplantation), Stanford University
Nima Farzan, CEO, PaxVax
Jenny Rooke, Managing Director, 5 Prime Ventures
Laurent Fischer, CEO, Tobira Therapeutics
Aarif Khakoo, VP Research and San Francisco Site Head, Amgen
Adams Dudley, Director, UCSF Center for Healthcare Value
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars